Aspero Medical Receives Seed Round Investment from Innosphere Fund
September 04, 2019 15:36 ET
|
Innosphere Fund
Colorado, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Innosphere Fund, a seed-stage venture fund that was formed to accelerate the growth and exit of Innosphere client companies, announced their second...
PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
July 15, 2019 09:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, July 15, 2019 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
Halitosis Treatment Market To Reach USD 23.21 Billion By 2026 | Reports And Data
June 04, 2019 12:56 ET
|
Reports And Data
Increase in the wide range of dental health product, and rise in periodontal diseases are boosting the growth of the market. Market Size – USD 7.90 Billion in 2018, Market Growth - CAGR of 13.1%,...
Provectus Announces Updated Results from Phase 1B Trial of PV-10 in Combination with KEYTRUDA® for Treatment of Advanced Melanoma at ASCO 2019
June 03, 2019 16:05 ET
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T cell populations similar...
Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019
June 03, 2019 09:05 ET
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...
Leading BioSciences to Present at Planet MicroCap Showcase 2019
April 25, 2019 08:05 ET
|
Leading BioSciences
CARLSBAD, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today...
Leading BioSciences to Present at Biotech Showcase 2019
January 02, 2019 08:05 ET
|
Leading BioSciences
CARLSBAD, Ca., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today announced...
Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors
October 30, 2018 08:05 ET
|
Leading BioSciences
Experienced Industry Executives Provide Company with Broad Life Science Industry Expertise Including Drug Development and Commercialization CARLSBAD, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) --...
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
July 31, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Ongoing Phase 1 basket study of PV-10 for cancers of the liver expanded to include single-center cohort of metastatic uveal melanoma patients Presentation of initial metastatic uveal melanoma data...
Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery
June 19, 2018 07:05 ET
|
Leading BioSciences
CARLSBAD, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today...